Drugs / 177Lu-JH040182
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07681141 | Apr 2025 → Dec 2026 expected | — | First Affiliated Hospital of Fujian Medical University | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-JH040182 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07681141 ↗ |
| Route | Intravenous | “received intravenous administration of 177Lu-JH040182” NCT07681141 ↗ |
| Target | FAP | “177Lu-JH040182, a novel FAP-targeted radiopharmaceutical” NCT07681141 ↗ |